Author

Michela Ballardini

Observed names: Ballardini, M., M Ballardini, M. Ballardini

Institution: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Observed institutions: University of Pisa, University of Verona, University of Modena and Reggio Emilia, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Santa Maria Nuova Hospital, Ospedale G.B. Morgagni - L.Pierantoni, Istituto Oncologico Romagnolo, University of Turin, University of Brescia, Sapienza University of Rome

OpenAlex ID: A5077458144

Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1

2009 · Sergio Pecorelli, Giuseppe Favalli, et al. · Journal of Clinical Oncology · 117

Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience

2004 · U. De Giorgi, T. Demirer, et al. · Annals of Oncology · 69

PDF

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study

2008 · Sandro Pignata, Gabriella Ferrandina, et al. · BMC Cancer · 51

PDF

The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy

2007 · Davide Tassinari, Luigi Montanari, et al. · Supportive Care in Cancer · 48

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

2006 · Ruggero Ridolfi, Massimiliano Petrini, et al. · Journal of Translational Medicine · 42

PDF

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

2007 · R Gunelli, E Bercovich, et al. · British Journal of Cancer · 38

PDF

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study

2009 · Sandro Pignata, Gabriella Ferrandina, et al. · Critical Reviews in Oncology/Hematology · 33

Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

2006 · Sandro Pignata, Gabriella Ferrandina, et al. · Oncology · 30

First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party

2004 · G Rosti, U De Giorgi, et al. · Bone Marrow Transplantation · 28

Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT)

2007 · P. F. Conte, G. Favalli, et al. · Journal of Clinical Oncology · 20

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study

2011 · Chiara Molinari, Michela Ballardini, et al. · Radiation Oncology · 17

PDF

Prognostic Factors in Patients With Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Chemotherapy

2008 · Andrea Mambrini, Claudio Bassi, et al. · Pancreas · 17

Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/ Platinum-Based Chemotherapy

2009 · Angiolo Gadducci, Dionyssios Katsaros, et al. · International Journal of Gynecological Cancer · 16

Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features

2009 · Ugo De Giorgi, Giovanni Rosti, et al. · Urologic Oncology Seminars and Original Investigations · 13

Do Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer?

2006 · Anna Maria Granato, Giovanni Luca Frassineti, et al. · Tumor Biology · 12

Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients

2009 · Laura Ridolfi, Giammaria Fiorentini, et al. · Melanoma Research · 8

High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II–IIIA breast cancer

2003 · U De Giorgi, G Rosti, et al. · Bone Marrow Transplantation · 5

Italian multicentric trial comparing chemotherapy with or without low-dose interleukin-2 (IL-2) in advanced non-small cell lung cancer: Results from a phase III randomized study

2009 · M. Ballardini, L. Ridolfi, et al. · Journal of Clinical Oncology · 1

P-22 Dendritic cell vaccination induces longer overall survival in immunoreactive advanced melanoma patients

2007 · Ruggero Ridolfi, Laura Ridolfi, et al. · Melanoma Research · 1

Supplementary Material for: Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

2007 · Pignata, S., Ferrandina, G., et al. · Figshare

Contents Vol. 71, 2006

2006 · Kiyoshi Ito, Hitoshi Niikura, et al. · Oncology

PDF

Acknowledgement to the Reviewers

2006 · Kiyoshi Ito, Hitoshi Niikura, et al. · Oncology

PDF

Works count: 23

Citation count: 566

H-index: 13

I10-index: 15